bioMérieux Develops Game Changing Quality Control Solution GENE-UP® PRO HRM
Developed in partnership with historic brand
The lengthy Compendial Method 15-day time-to-result forces juice and concentrate producers to decide between incurring costly storage fees until test results are received or forgoing the waiting period and risk shipping spoilage-prone products. The reduced time-to-result with GENE-UP® PRO HRM fuels improved operational efficiencies, minimizes manufacturer storage costs, and safeguards brand reputation among consumers.
"bioMérieux is a longstanding diagnostic partner of the beverage industry, and we're always up for the challenge of solving our customer's toughest spoilage problems," said
While typically posing no public health or safety risk, in recent years heat-resistant molds have become a top quality concern and operational bottleneck for beverage and concentrate manufacturers. Unlike other yeast and mold test kits in the market, GENE-UP® PRO HRM is an innovative and complete testing solution that targets ascospore profiles to ultimately determine the presence of viable heat-resistant molds, resulting in the most comprehensive and reliable testing solution available today.
"Our loyal consumers have come to trust the high quality of our products and the integrity of our brand," notes
GENE-UP® PRO HRM can be implemented alongside bioMérieux's GENE-UP® PRO ACB, a real-time PCR assay that detects and predicts spoilage due to Alicyclobacillus, causing off flavors and aromas in finished juice products. Together, the offering collectively speeds up and boosts confidence in the quality process across all major beverage spoilage concerns while also reducing costs and improving yield. Both GENE-UP® PRO HRM and GENE-UP® PRO ACB are a result of bioMérieux's xPRO™ Program, an innovation engine within bioMérieux that challenges the status quo to advance molecular diagnostics.
To learn more about how GENE-UP® PRO HRM, GENE-UP® PRO ACB, or bioMérieux's other game-changing xPRO™ solutions can unlock operational efficiencies and cost savings, please visit https://www.biomerieux.com/us/en/our-offer/industry-products/gene-up-pro-hrm.html.
ABOUT BIOMÉRIEUX
Pioneering Diagnostics
A world leader in the field of in vitro diagnostics since 1963, bioMérieux is present in 45 countries and serves more than 160 countries with the support of a large network of distributors. In 2024, revenues reached €4 billion, with over 93% of sales outside of
bioMérieux provides diagnostic solutions (systems, reagents, software and services) which determine the source of disease and contamination to improve patient health and ensure consumer safety. Its products are mainly used for diagnosing infectious diseases. They are also used for detecting microorganisms in agri-food, pharmaceutical and cosmetic products.
www.biomerieux.com.
bioMérieux is listed on the
Symbol: BIM – ISIN Code: FR0013280286
Reuters: BIOX.PA/Bloomberg: BIM.FP
CONTACTS
INVESTORS RELATIONS |
|
|
bioMérieux |
|
|
|
|
|
Tel: +33 (0)4 78 87 20 00 |
|
|
|
|
|
|
|
|
MEDIA RELATIONS |
|
|
bioMérieux |
bioMérieux |
|
|
|
|
Tel: +33 (0)4 78 87 20 00 |
Tel: (331) 385 1332 |
Tel: (717) 413 0370 |
|
|
|
View original content to download multimedia:https://www.prnewswire.com/news-releases/biomerieux-develops-game-changing-quality-control-solution-gene-up-pro-hrm-302522374.html
SOURCE bioMérieux